ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1541

Effect of Rituximab on Long-term Damage Acquisition in Patients with Systemic Lupus Erythematosus
Abstract Number: 1542

Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus
Abstract Number: 1543

Improvements in BILAG Musculoskeletal and Mucocutaneous Domains at Week 48 in a Phase 2 Double-Blind Placebo-Controlled Trial of ABBV-599 (Elsubrutinib + Upadacitinib Combination) and Upadacitinib Monotherapy for Treatment of Moderately to Severely Active Systemic Lupus Erythematosus
Abstract Number: 1544

Comparison of Efficacy and Safety Between Belimumab and Telitacicept in the Treatment of Systemic Lupus Erythematosus
Abstract Number: 1545

Rates of Sustained Complete Renal Response with Long-term Use of Voclosporin in AURORA 2
Abstract Number: 1546

Characteristics and Treatment Patterns of Patients with Lupus Nephritis: A Retrospective Claims Database Study in the USA
Abstract Number: 1547

Hydroxychloroquine and Prednisone Use by Individuals Diagnosed with Systemic Lupus Erythematosus in the TriNetX Research Database
Abstract Number: 1548

Anifrolumab in Systemic Lupus Erythematosus. Spanish National Registry in a Real-world Setting
Abstract Number: 1549

Prescribing Trends for Novel Treatments in Systemic Lupus from 2017 to 2022
Abstract Number: 1550

CD19 CAR T Cell Therapy Suppresses the Inflammatory Profile of Neutrophils in Systemic Lupus Erythematosus
Abstract Number: 1551

Efficacy of Belimumab on Different Phenotypes of Joint and Skin Manifestations of Systemic Lupus Erythematosus: Preliminary Data from a Multicenter, Nationwide, Cohort of Patients: The BElimumab in Real Life Setting Study-New Joint and Skin (BeRLISS-NeJS)
Abstract Number: 1552

Kinetics of Mucocutaneous and Musculoskeletal Responses to Deucravacitinibin Patients with Active SLE in the Phase 2 PAISLEY Trial
Abstract Number: 1553

Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)
Abstract Number: 1554

Belimumab Increases SLE Responder Index-4 Response Rates versus Placebo in Early Active Systemic Lupus Erythematosus: A Large Integrated Analysis of Belimumab Trials
Abstract Number: 1555

Sustained Functional Assessment of Chronic Illness Therapy–Fatigue Response in Patients with SLE Receiving Anifrolumab Alongside Standard Therapy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].